Clinical trials: Malignant Mesenchymal Tumor
Resectable Soft Tissue Sarcoma, Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
Radiation Therapy Before Surgery for Localized, Resectable Soft Tissue Sarcoma of the Extremity and Superficial Trunk
This phase II trial investigates the effects of hypofractionated radiation therapy before surgery on wound complications associated with surgery in treating patients with soft tissue sarcoma of the extremity (arms, hands, legs or…
- Conditions
- Resectable Soft Tissue Sarcoma, Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
- Trial name
- NCT04562480
- Testing
- Hypofractionated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Mayo Clinic
Sarcoma, Alveolar Soft Part Sarcoma (ASPS)
CAR T Therapy With GCAR1 for Relapsed Alveolar Soft Part Sarcoma
A single patient study to determine whether GCAR1 is safe and effective for re-treatment of alveolar soft part sarcoma (ASPS) with GPNMB surface expression that has relapsed and is not responding to usual treatment.
- Trial name
- SPS-Q2 (NCT06813417)
- Testing
- GCAR1
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- University of Calgary
Breast Cancer, Colon Cancer
Genomic Structural Variation in Cancer Susceptibility
This study will look for new types of gene changes that may be related to cancer in some patients. Some gene changes (mutations) are passed on from parents to offspring (child).
- Conditions
- Breast Cancer, Colon Cancer, Germ Cell Cancer, Neuroblastoma
- Trial name
- NCT00996710
- Where
- United States
- Volunteers
- 1,275 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Colorectal Cancer
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
RATIONALE: Sorafenib and pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00703638
- Testing
- cisplatin, pemetrexed disodium, sorafenib
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Breast Cancer, Lung Cancer
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
This study will investigate the effects of atezolizumab on select cancer types in people whose analysis of tumour DNA and RNA indicates they may be sensitive to atezolizumab.
- Conditions
- Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Genitourinary Cancer
- Trial name
- CAPTIV-8 (NCT04273061)
- Testing
- Atezolizumab
- Where
- 2 sites in Canada
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
Sarcoma
Biomarkers in Samples From Young Patients With Soft Tissue Sarcoma
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT01342783
- Testing
- DNA analysis, RNA analysis, mutation analysis
- Volunteers
- 20 people
- Sponsor
- Children's Oncology Group
DLBCL - Diffuse Large B Cell Lymphoma, R-CHOP Chemotherapy
Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL
To evaluate the efficacy and safety of pirtobrutinib combined with R-CHOP in patients with newly diagnosed non-GCB diffuse large B-cell lymphoma (DLBCL)
- Conditions
- DLBCL - Diffuse Large B Cell Lymphoma, R-CHOP Chemotherapy, Pirtobrutinib
- Trial name
- NCT07744737
- Testing
- Pirtobrutinib plus R-CHOP
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Changzhou No.2 People's Hospital
Advanced Soft-tissue Sarcoma, Advanced Epithelioid Sarcoma
Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
The participants of this study will have advanced epithelioid sarcoma. Sarcoma is a cancer of the connective tissues, such as nerves, muscles and bones. Epithelioid sarcoma is an ultra-rare sarcoma of the soft-tissue.
- Trial name
- NCT04204941
- Testing
- Tazemetostat, Doxorubicin HCl
- Where
- 21 sites in United States, Canada and 2 more
- Volunteers
- 25 people
- Sponsor
- Epizyme, Inc.
Chondrosarcoma
Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Low and Inter-mediate Grade Chondrosarcoma of the Skull Base
The study is a prospective randomised clinical phase III trial. Proton therapy is the gold standard in the treatment of low and intermediate grad chondrosarcomas of the skull base.
- Trial name
- CSP12C (NCT01182753)
- Testing
- carbon ion therapy, proton therapy
- Where
- Germany
- Volunteers
- 154 people
- Sponsor
- Heidelberg University
Solid Tumours, Sarcoma
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which…
- Conditions
- Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer
- Trial name
- INVOKE (NCT06789172)
- Testing
- OKN4395, Pembrolizumab, Fasting
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 146 people
- Sponsor
- Epkin
Ewing's Sarcoma
Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma
Controlled, randomized phase III study, with the intent of optimizing the treatment of not metastatic Ewing Sarcoma. The patients will be randomized into 2 arms: standard treatment vs intensive treatment.
- Trial name
- EW-1 (NCT02063022)
- Testing
- Standard treatment (as per protocol ISG SSG III), Intensified chemotherapy
- Where
- 14 sites in Italy
- Volunteers
- 278 people
- Sponsor
- Italian Sarcoma Group
Sarcoma,Soft Tissue
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
To compare Overall Survival (OS) for INT230-6 vs United States (US) Standard of Care (SOC) in participants with unresectable or metastatic liposarcoma, undifferentiated pleomorphic sarcoma or leiomyosarcoma who have disease…
- Trial name
- INVINCIBLE-3 (NCT06263231)
- Testing
- INT230-6, Eribulin, Trabectedin
- Where
- 17 sites in United States, Canada and 3 more
- Volunteers
- 333 people
- Sponsor
- Intensity Therapeutics, Inc.
Sarcoma
Hyper-Thermia Enhanced Anti-tumor Efficacy of Trabectedin
This trial compares trabectedin alone to trabectedin in combination with regional hyperthermia in patients with high-risk soft tissue sarcoma.
- Trial name
- HyperTET (NCT02359474)
- Testing
- Trabectedin, DNA double-strand breaks
- Where
- 5 sites in Germany
- Volunteers
- 120 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Pancreatic Ductal Adenocarcinoma, KRAS G12D
Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma
This is an open-label expanded access protocol (EAP) of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides 7P])…
- Conditions
- Pancreatic Ductal Adenocarcinoma, KRAS G12D, KRAS G12V, KRAS G12S
- Trial name
- AMPLIFY-EAP (NCT07083479)
- Testing
- ELI-002 7P
- Sponsor
- Elicio Therapeutics
Advanced Malignant Mesothelioma, Carcinoma of the Appendix
Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
RATIONALE: An orientation and patient education program and telephone counseling may help improve the quality of life in patients with peritoneal surface malignancies.
- Conditions
- Advanced Malignant Mesothelioma, Carcinoma of the Appendix, Ovarian Sarcoma, Ovarian Stromal Cancer
- Trial name
- HOPE (NCT01126346)
- Testing
- HIPEC Orientation, Consultation with Survivorship Navigator, Questionnaires
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Wake Forest University Health Sciences
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Liver Cancer
- Trial name
- NCT00007813
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma
BMS-247550 in Treating Patients With Advanced Soft Tissue Sarcoma
Phase II trial to study the effectiveness of BMS-247550 in treating patients who have advanced soft tissue sarcoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
- Trial name
- NCT00022542
- Testing
- ixabepilone
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Sarcoma
Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors
2.1 Primary Objectives 1. To measure the human dosimetry of 64Cu-DOTA-U3-1287 in subjects with advanced solid tumors (Cohort 1 only) 2.
- Conditions
- Carcinoma, Sarcoma, Lymphoma
- Trial name
- NCT01479023
- Testing
- 64Cu-DOTA-U3-1287, U3-1287 (unlabeled)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Washington University School of Medicine
Osteosarcoma, Bone Cancer
Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma
The goal of this clinical trial is to learn the efficacy and safety of intra-arterial cisplatin plus anti-angiogenesis inhibitor rh-endostatin (Endostar) combined with systematic chemotherapy in osteosarcoma.
- Trial name
- IACE-OS (NCT06562673)
- Testing
- intra-arterial cisplatin plus anti-angiogenesis inhibitor rh-endostatin (Endostar)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai 6th People's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.